Day: January 6, 2022

Gilat receives order for additional VSATs to enable the operator’s 4G/LTE network growth PETAH TIKVA, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today it has received an order for additional VSATs from its Tier-1 mobile network carrier customer in Japan. Using Gilat’s unique SkyEdge II-c cellular backhaul system, the mobile network carrier will be expanding their cellular backhaul over satellite. This will enable further growth of their 4G/LTE network into rural zones that are lacking fiber access. “This additional order is a vote of confidence and a testament to the quality and effectiveness of our cellular backhaul over satellite solution,” said Michal Aharonov, Chief Commercial...

FOSTER CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced the appointment of Jeffrey R. Jasper, Ph.D., as senior vice president, head of research. Dr. Jasper joins Terns with more than 28 years of experience in the biopharmaceutical industry. Terns also announced the promotion of Diana Chung to senior vice president, chief development officer. Both Dr. Jasper and Ms. Chung will report to Erin Quirk, M.D., president, head of research and development and chief medical officer. “Attracting top talent and developing our management team is essential...

Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 6 January 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces that management will participate in the virtual 40th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 12, 2022 at 7:30 a.m. Eastern Time (ET). The presentation and Q&A session will be webcast live during the conference and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentation...

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) — DarkPulse Inc. (OTC: DPLS) (“DPLS” or “the Company”), with the full support of its board of directors, today announced its intention to take its wholly-owned subsidiary, Optilan (“Optilan”), public in the U.S. in mid-2022 via an initial public offering (IPO). Management believes the move will unlock the value of Optilan for DarkPulse shareholders by creating a separate publicly traded company and will build on Optilan’s successful track record and serve to expand its markets. The Company anticipates that Optilan will apply for listing on the New York Stock Exchange (“NYSE”) directing towards public offering upon acceptance. The number of shares to be offered and the price range for the proposed offering is yet to be determined; however, the Company plans to...

SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Brilliant Earth (NASDAQ: BRLT), an innovative, digital-first jewelry company and global leader in ethically sourced fine jewelry, today announced that the Company will participate in the 24th Annual ICR Conference being held virtually from Monday, January 10, 2022 through Wednesday, January 12, 2022. Beth Gerstein, Chief Executive Officer and Co-Founder, will participate in a fireside chat on Tuesday, January 11, 2022, at 11:00 a.m. Eastern Standard Time. The Company’s management team will meet with investors during the conference. The audio portion of the fireside chat will be available on the Company’s Investor Relations website, https://investors.brilliantearth.com and will remain available for 90 days following the event. About Brilliant Earth  Brilliant Earth is a digitally...

SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Patent and Trademark Office has issued two new patents covering the company’s FIN-211 enriched consortia microbiome product candidate in development for children with autism spectrum disorder (ASD) and significant gastrointestinal (GI) symptoms. The company’s intellectual property portfolio now includes 59 issued U.S. and foreign patents with more than 130 patent applications pending. The first patent (U.S. Patent No. 11,202,808) covers key technologies involved in addressing ASD and GI symptoms associated with...

MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) — Intema Solutions Inc. (“Intema” or the “Corporation”) (TSXV: ITM, OTCMKTS: ITMZF) announces that it has received proceeds of $1,574,400 from the exercise of warrants into 13,120,000 common shares of the Corporation. Intema is also pleased to report on the outcome of its annual general and special meeting of shareholders, held on Tuesday, January 4, 2022, in a virtual-only format. At the meeting, the Corporation’s shareholders approved all the resolutions set out in the management proxy circular dated December 6, 2021, including those on the election of directors, the appointment of MGO LLP as the new auditors of the Corporation for the coming year and the approval of a 10% rolling stock option plan. The shareholders also approved the name change of the Corporation to React Gaming Group...